New Data Shows Heart Failure Treatment Guided by Daxor’s BVA-100® Lowers Hospital Length of Stay by 55%
October 03, 2022 09:00 ET
|
Daxor Corporation
Patients Receiving BVA Stayed 2.5 Fewer Days in Hospital Resulting in Reduced Costs of Care Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation, the global leader in blood volume...
New Data Shows 85% Reduction In One-Year Mortality For Medicare Heart Failure Patients With BVA-Guided Care
October 03, 2022 08:40 ET
|
Daxor Corporation
Patient One-Year Mortality Rate 5.6% with BVA-Guided Care Compared to 36.8% in Control Group - Data Presented at Key Scientific Meeting Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor...
New Studies Validating the Uniqueness of the BVA-100® Blood Test for Heart Failure Patients Compared to Pressure Measures
October 03, 2022 08:00 ET
|
Daxor Corporation
Presented at Key Scientific Society Meeting -Commonly Used Pressure Measures for Volume Assessment Proven Not Equivalent to BVA Oak Ridge, TN, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
Daxor Corporation to Exhibit at the Annual Scientific Meeting of the Heart Failure Society of America
September 26, 2022 08:00 ET
|
Daxor Corporation
Compelling New Patient Outcome Data to be Presented Oak Ridge, TN, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology,...
Daxor Corporation to Attend the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 17:05 ET
|
Daxor Corporation
Oak Ridge, TN, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh...
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
August 29, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it issued a corporate update in a Letter...
Daxor Corporation Reports a 92.6 Percent Revenue Increase in Diagnostic Operating Division in Form N-CSR Filing for the Six Months Ended June 30, 2022
August 25, 2022 16:05 ET
|
Daxor Corporation
Conference Call to be held today at 4:30 p.m. Eastern Time Oak Ridge, TN, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology,...
Daxor Corporation to Report First Half 2022 Financial Results on Thursday, August 25, 2022, and Provide Corporate Update
August 24, 2022 16:40 ET
|
Daxor Corporation
Conference Call to be held on the same day at 4:30 p.m. Eastern Time Oak Ridge, TN, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement...
Daxor Corporation Announces a 49.4% Increase In Its Single-Use Diagnostic Kits Year-Over-Year and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.
July 27, 2022 08:00 ET
|
Daxor Corporation
Oak Ridge, TN, July 27, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today an unaudited increase of 49.4% in sales of...
DAXOR CORPORATION ANNOUNCES PARTNERSHIP WITH MEDAXIOM TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100®)
July 21, 2022 08:00 ET
|
Daxor Corporation
Daxor Has Exclusive Access to the Cardiovascular Industry's Most Comprehensive and Powerful Network of Executives and Clinicians - Sharing Best Practices, Guidance and Resources to Dramatically...